Springer Seminars in Immunopathology

, Volume 8, Issue 4, pp 401–412 | Cite as

New approaches for control of infections using synthetic or semi-synthetic constructs containing MDP

  • Louis Chedid
  • Françoise Audibert
Article

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Audibert F, Chedid L (1980) New developments with human and veterinary vaccines. Prog Clin Biol Res A., 47: 325Google Scholar
  2. 2.
    Audibert F, Chedid L (1984) Of antigens, adjuvants and carriers in synthetic vaccines. In: Chanock RM, Lerner RA (eds) Modern approaches to vaccines. Molecular and chemical basis of virus virulence and immunogenicity. Cold Spring Harbor Laboratory, Cold Spring Harbor, p 397Google Scholar
  3. 3.
    Audibert F, Chedid L, Hannoun C (1977) Augmentation de la résponse immunitaire an vaccin grippal par un glycopeptide synthétique adjuvant (N-acétylmuramyl-L-alanyl-D-isoglutamine). CR Seances Acad Sci [III] 285: 467Google Scholar
  4. 4.
    Audibert F, Jolivet M, Chedid L, Alouf JE, Boquet P, Rivaille P, Siffert O (1981) Active antitoxic immunization by a diphtheria toxin synthetic oligopeptide. Nature 289: 593PubMedGoogle Scholar
  5. 5.
    Audibert F, Jolivet M, Chedid L, Arnon R, Sela M (1982) Successful immunization with a totally synthetic diphtheria vaccine. Proc Natl Acad Sci USA 79: 5042PubMedGoogle Scholar
  6. 6.
    Audibert FM, Przewlocki G, Leclerc CD, Jolivet ME, Gras-Masse HS, Tartar AL, Chedid, LA (1984) Enhancement by NAcMur-L-Ala-D-Gln-α-n-butyl-ester (Murabutide) of the immune response to natural and synthetic hepatitis B surface antigens. Infect Immun 45: 261PubMedGoogle Scholar
  7. 7.
    Beachey EH, Seyer JM, Dale JB, Simpson, WA, Kang A (1981) Type-specific protective immunity evoked by synthetic peptide ofStreptococcus pyogenes M protein. Nature 292: 457PubMedGoogle Scholar
  8. 8.
    Bittle JL, Worcel P, Houghten, RA, Lerner RA, Rowlands DJ, Brown F (1984) Immunization with a chemically synthesized peptide derived from foot-and-mouth disease virus polypeptide VP1. In: Chanock RM, Lerner RA (eds) Proceedings of the “Modern approaches to vaccines”. Molecular and chemical basis of virus virulence and immunogenicity. Cold Spring Harbor Laboratory, Cold Spring Harbor, p 103Google Scholar
  9. 9.
    Butler JE, Richerson HB, Swanson PA, Kopp WC, Suelzer MT (1983) The influence of muramyl dipeptide on the secretory immune response. In: McGhee JR, Mestecky J (eds) The secretory immune system. Ann NY Acad Sci 409: 669Google Scholar
  10. 10.
    Carelli C, Audibert F, Chedid L (1981) Persistent enhancement of cell-mediated and antibody immune responses after administration of MDP derivatives with antigen in metabolisable oil. Infect Immun 33: 312PubMedGoogle Scholar
  11. 11.
    Carelli C, Audibert F, Chedid L, Gaillard J (1982) Immunological castration of male mice by a totally synthetic vaccine (LH-RH conjugated to MDP administered in saline. Proc Natl Acad Sci USA 79: 5392PubMedGoogle Scholar
  12. 12.
    Chanock RM, Lerner RA (1984) Modern approaches to vaccines. Molecular and chemical basis of virus virulence and immunogenicity. Cold Spring Harbor Larboratory, Cold Spring HarborGoogle Scholar
  13. 13.
    Chedid L (1983) Muramyl peptides as possible endogenous immunopharmacological mediators. Microbiol Immunol 27: 723.PubMedGoogle Scholar
  14. 14.
    Chedid L, Parant M, Parant F, Lefrancier P, Choay J, Lederer E (1977) Enhancement of nonspecific immunity toKlebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetyl-muramyl-Lalanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci USA 74: 2089PubMedGoogle Scholar
  15. 15.
    Chedid LA, Parant MA, Audibert FM, Riveau GJ, Parant FJ, Lederer E, Choay JP (1982) Biological activity of a new synthetic muramyl peptide adjuvant of pyrogenicity. Infect Immun 35: 417PubMedGoogle Scholar
  16. 16.
    Chedid L, Jolivet M, Audibert F, Przewlocki G, Beachey EH, Gras-Mase H, Tartar A (1983) Antibody responses elicited by a polyvalent vaccine containing synthetic diphtheric, streptococcal and hepatitis peptides coupled to the same carrier. Biochem Biophys Res Commun 117: 908PubMedGoogle Scholar
  17. 17.
    Chedid L, Carelli C, Audibert F (1984) Use of adjuvants, antigens and carriers in synthetic veterinary vaccines. In: Proceedings advances in carriers and adjuvants for veterinary biologics Symposium. Ames, USA, May 7–8. Rev: Infect. Dis (in press)Google Scholar
  18. 18.
    Clough ER, Audibert FM, Barnwell JW, Schlesinger DH, Arnon R, Chedid LA (1985) Biologically active antibodies elicited by a synthetic circumsporozoite peptide ofPlasmodium knowlesi administered in saline with an MDP derivative. Infect Immun 48: 839PubMedGoogle Scholar
  19. 19.
    Cryz SJ, Friedman RL, Pavlovskis OR, Iglewski BH (1981) Effect of formalin toxoiding onPseudomonas aeruginosa toxin A: Biological, chemical and immunochemical studies. Infect Immun 32: 759PubMedGoogle Scholar
  20. 20.
    Davenport FM (1968) Seventeen years' experience with mineral oil adjuvant influenza virus vaccines. Ann Allergy 26: 288PubMedGoogle Scholar
  21. 21.
    Dietrich FM, Sackmann W, Zak O, Dukor P (1980) Synthetic muramyl dipeptide immunostimulants: Protective effects and increased efficacy antibiotics in experimental bacterial and fungal infections in mice. In: Nelson JD, Grassi C (eds) Current chemotherapy and infectious disease, Vol. 2. Am Soc Microbiol, Washington DC, Proc. 11th ICC and 19th ICAAC, p 1730Google Scholar
  22. 22.
    Dietrich FM, Lukas B, Schmidt-Rupin KH (1983) MTP-PE (synthetic muramyl peptide): Prophylactic and therapeutic effects in experimental viral infections. Communicated at 13th Intern. Congress of Chemotherapy, Vienna, Aug. 28–Sept. 2.Google Scholar
  23. 23.
    Durette P, Dorn C, Friedman A, Schlabach A (1982) Synthesis and immunoadjuvant activities of 2-acetamido-5-0-acetyl-6-0-acetyl-2-deoxy-3-0-(R)-2-propionyl-L-al anyl-D-isoglutamine-D-glucofuranoses as potential prodrug forms of 6-0-acyl derivatives of N-acetylmuramyl dipeptide. J Med Chem 25: 1028PubMedGoogle Scholar
  24. 24.
    Edelman R (1980) Vaccine adjuvants. Rev Infect Dis 2: 370PubMedGoogle Scholar
  25. 25.
    Ellouz F, Adam A, Ciorbaru R, Lederer E (1974) Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 59: 1317PubMedGoogle Scholar
  26. 26.
    Ferguson TA, Krieger NJ, Pesce A, Michael JG (1983) Enhancement of antigen-specific suppression by muramyl dipeptide. Infect Immun 39: 800PubMedGoogle Scholar
  27. 27.
    Fraser HM (1980) Inhibition of reproductive function by antibodies to luteinizing hormone-releasing hormone. In: Hearn JP (ed) Aspects of reproduction and fertility control. MTP Press Ltd, Falcon House, Lancaster, p 143Google Scholar
  28. 28.
    Fraser-Smith EB, Matthews TR (1981) Protective effects of muramyl dipeptide analogs against infections ofPseudomonas aeruginosa orCandida albicans in mice. Infect Immun 34: 676PubMedGoogle Scholar
  29. 29.
    Friedman H, Warren G (1984) Muramyl dipeptide-induced enhancement of phagocytosis of antibiotic pretreatedEscherichia coli by macrophages. Proc Soc Exp Biol Med 176: 366PubMedGoogle Scholar
  30. 30.
    Genco RJ, Linzer R, Evans RT (1983) Effect of adjuvants on orally administered antigens. In: McGhee JR, Mestecky J (eds) The secretory immune system. Ann NY Acad Sci 409: 650Google Scholar
  31. 31.
    Goebel WF (1939) Studies on antibacterial immunity induced by artificial antigens. I. Immunity to experimental pneumococcal infection with an antigen containing cellobiuronic acid. J Exp Med 69: 53Google Scholar
  32. 32.
    Gysin J, Barnwell JW, Schlesinger DH, Nussenzweig V, Nussensweig RS (1984) Neutralization of the infectivity of sporozoites ofPlasmodium knowlesi by antibodies to a synthetic peptide. J Exp Med 160: 935PubMedGoogle Scholar
  33. 33.
    Herzenberg LA, Tokuhisa T, Parks DR, Herzenberg LA (1982) Epitope-specific regulation. II. A bistable, Igh-restricted regulatory mechanism central to immunologic memory. J Exp Med 155:1741PubMedGoogle Scholar
  34. 34.
    Hilleman MR (1985) Newer directions in vaccine development and utilization. J Infect Dis 151: 407PubMedGoogle Scholar
  35. 35.
    Humphries RC, Heniki PR, Ferraresi RW, Krahenbuhl JL (1980) Effects of treatment with muramyl dipeptide and certain of its analogs on resistance toListeria monocytogenes in mice. Infect Immun 30: 462PubMedGoogle Scholar
  36. 36.
    Jolivet M, Audibert F, Beachey EH, Tartar A, Gras-Masse H, Chedid L (1983) Epitope-specific immunity elicited by a synthetic streptococcal antigen without carrier or adjuvant. Biochem Biophys Res Commun 117: 359PubMedGoogle Scholar
  37. 37.
    Kierszenbaum F, Ferraresi RW (1979) Enhancement of host resistance againstTrypanosoma cruzi infection by the immunoregulatory agent muramyl dipeptide. Infect Immun 25: 273PubMedGoogle Scholar
  38. 38.
    Kishimoto T, Hirai Y, Nakanishi K, Azuma I, Nagamatsu A, Yamamura Y (1979) Regulation of antibody response in different immunoglobulin classes. VI. Selective suppression of IgE response by administration of antigen-conjugated muramyl peptides. J Immunol 123: 2709PubMedGoogle Scholar
  39. 39.
    Koff WC, Fidler IJ, Showalter SD, Chakrabarty MK, Hampar B, Ceccorulli LM, Kleinerman ES (1984) Human monocytes activated by immunomodulators in liposomes lyse herpes virus-infected but not normal cells. Science 224: 1007PubMedGoogle Scholar
  40. 40.
    Kotani S, Watanabe Y, Kinoshita F, Shimono T, Morisaki I, Shiba T, Kusomoto S, Tarumi Y, Ikenaka K (1975) Immunoadjuvant activities of synthetic N-acetylmuramyl peptides or -amino acid. Biken J 18: 105PubMedGoogle Scholar
  41. 41.
    Kotoni S, Watanabe Y, Shimono T, Harada K, Shiba T, Kusumoto S, Yokogawa K, Taniguchi M (1976) Correlation between the immunoadjuvant activities and pyrogenicities of synthetic Nacetylmuramyl peptides or amino acids. Biken J 19: 9PubMedGoogle Scholar
  42. 42.
    Kotani S, Takada H, Tsujimoto M, Ogawa T, Mori Y, Koga T, Iribe H, Tanaka A, Nagao S, McGhee JR, Michalek SM, Morisaki I, Nishimura C, Ikeda S, Kohashi O, Ogawa S, Hamada S, Kawata S, Shiba T, Kusumoto S (1983) Lipophilic muramyl peptides and synthetic lipid A analogs as immunomodulators. In: Yamamura Y. Tada T (eds) Progress in immunology V. Academic Press, Japan, p 1359Google Scholar
  43. 43.
    Krahenbuhl JL, Humphres RC (1983) Effects of treatment with muramyl dipeptide on resistance toMycobacterium leprae andMycobacterium marinum infection in mice. Immunopharmacology 5: 329PubMedGoogle Scholar
  44. 44.
    Krueger JM, Walter J, Karnovsky ML, Chedid L, Choay JP, Lefrancier P, Lederer E (1984) Muramyl peptides. Variation of somnogenic activity with structure. J Exp Med 159: 68PubMedGoogle Scholar
  45. 45.
    Leclerc C, Audibert F, Chedid L (1978) Influence of a synthetic adjuvant (MDP) on qualitative and quantitative changes of serum globulins. Immunology 35: 963PubMedGoogle Scholar
  46. 46.
    Leclerc C, Morin A, Chedid L (1983) Potential use of synthetic muramyl peptides as immunoregulating molecules. In: Thompson RA, Rose NR (eds) Recent advances in clinical immunology, Vol 3. Churchill Livingstone, Edinburgh, p 187Google Scholar
  47. 47.
    Lederer E (1980) Synthetic immunostimulants derived from the bacterial cell wall. J Med Chem 23: 819PubMedGoogle Scholar
  48. 48.
    Lefrancier P, Lederer E (1981) Chemistry of synthetic immunomodulant muramyl peptides. Prog Chem Org Nat Prod 40: 1Google Scholar
  49. 49.
    Le Jan C, Asso J (1980) Les immunostimulants orientent la réponse locale au virus de l'IBR vers la production d'interféron. Comp Immunol Microbiol Infect Dis 3: 485PubMedGoogle Scholar
  50. 50.
    Lukas B, Schmidt-Rupin KH, Dietrich FM (1983) Prophylactic and therapeutic effects of MTP-PE, a synthetic muramyl peptide, in experimental virus infections. Proc. Intern. Symp. on Immunomodulation by Chemically-Defined Adjuvants. Sapporo, Japan, p 42Google Scholar
  51. 51.
    MacKaness GB, Lagrange PH, Ishibashi T (1974) The modifying effect of BCG on the immunological induction of T-cells. J Exp Med 139: 1540PubMedGoogle Scholar
  52. 52.
    Masihi KN, Brehmer W, Azuma I, Lange W, Muller S (1984) Stimulation of chemiluminescence and resistance against aerogenic influenza virus infection by synthetic muramyl dipeptide combined with trehalose dimycolate. Infect Immun 43: 233PubMedGoogle Scholar
  53. 53.
    Matthews TR, Fraser-Smith EB (1980) Protective effect of muramyl dipeptide and analogs againstPseudomonas aeruginosa andCandida albicans infections in mice. In: Current chemotherapy of infectious disease. Proceedings of the 11th Intern. Congress of Chemotherapy 2. Am Soc Microbiol, Washington DC, p 1734Google Scholar
  54. 54.
    Morisaki I, Michalek SM, Harmon CC, Torii M, Hamada S, McGhee JR (1983) Effective immunity to dental caries: Enhancement of salivary anti-Streptococcus mutans antibody responses with oral adjuvants. Immun 40: 577Google Scholar
  55. 55.
    Nash HA, Chang CC, Tsong YY (1985) Formulation of a potential antipregnancy vaccine based on theβ-subunit of human chorionic gonadotropin (β-hCG). II. Use of compounds of the muramyl dipeptide (MDP) family as adjuvants. J Reprod Immunol 7: 151PubMedGoogle Scholar
  56. 56.
    Ohkuni H, Norose Y, Ohta M, Hamaya M, Kimura Y, Tsujimoto M, Kotani S, Shiba T, Kusomoto S, Yokogawa K, Kawata S (1979) Adjuvant activities in production of reaginic antibody by bacterial cell wall peptidoglycan or synthesisN-acetylmuramyl dipeptides in mice. Infect Immun 24: 313PubMedGoogle Scholar
  57. 57.
    Onozuka K, Saito-Taki T, Nakano M (1984) Effect of muramyl dipeptide analog onSalmonella enteritidis infection in beige mice with Chediak-Higashi syndrome. Microbiol Immunol 28: 1211PubMedGoogle Scholar
  58. 58.
    Otani T, Katami K, Une T, Osada Y, Ogawa H (1984) Restoration by MDP-Lys(L 18) of resistance toPseudomonas pneumonia in immunosuppressed guinea pigs. Microbiol Immunol 28: 1077PubMedGoogle Scholar
  59. 59.
    Parant M (1979) Biologic properties of a new synthetic adjuvant, muramyl dipeptide (MDP). Springer Semin Immunopathol 2: 101Google Scholar
  60. 60.
    Parant M, Parant F, Chedid L (1978) Enhancement of the neonate's nonspecific immunity to Klebsiella infection by muramyl dipeptide, a synthetic immunoadjuvant. Proc Natl Acad Sci USA 75: 3395PubMedGoogle Scholar
  61. 61.
    Prouvost-Danon A, Bahr GM, Chedid L, Ekwalanga M, Bassot S (1984) In vivo effects of ovalbuminconjugated muramyl peptides on the anti-ovalbumin IgE and IgG responses in mice. Int J Immunopharmacol 6: 425PubMedGoogle Scholar
  62. 62.
    Reese TR, Trager W, Jensen JB, Miller DA, Tantravehi R (1978) Immunization against malaria with antigen fromPlasmodium falciparum cultivated in vitro. Proc Natl Acad Sci USA 75: 5665PubMedGoogle Scholar
  63. 63.
    Richerson HB, Suelzer MT, Swanson PA, Butler JE, Kopp WC, Rose EF (1982) Chronic hypersensitivity pneumonitis produced in the rabbit by the adjuvant effect of inhaled muramyl dipeptide (MDP). Am J Pathol 106: 409PubMedGoogle Scholar
  64. 64.
    Sakuma T, Azuma M, Yoshida I (1984) Effect of N-acetylmuramyl-L-alanyl-D-isoglutamine on interferon production in mice by Newcastle disease virus. J Gen Virol 65: 999PubMedGoogle Scholar
  65. 65.
    Siddiqui WA, Taylor DW, Kan SC, Kramer K, Richmond-Crum SM, Kotani S, Shiba T, Kusomoto S (1978) Vaccination of experimental monkeys againstPlasmodium falciparum: A possible safe adjuvant. Science 201: 1237PubMedGoogle Scholar
  66. 66.
    Souvannavong V, Adam A, Lederer E (1978) Kinetics of the humoral and cellular immune response of guinea pigs after injection of the synthetic adjuvant N-acetylmuramyl-L-alanyl-D-isoglutamine: Comparison with Freund complete adjuvant. Infect Immun 19: 966PubMedGoogle Scholar
  67. 67.
    Stevens VC, Cinader B, Powell JE, Lee AC, Koh SW (1981) Preparation and formulation of a human chorionic gonadotropin anti-fertility vaccine: Selection of adjuvant and vehicle. Am J Reprod Immunol 1: 315Google Scholar
  68. 68.
    Taubman MA, Ebersole JL, Smith DJ, Stack W (1983) Adjuvants for secretory immune responses. In: McGhee JR, Mestecky J (eds) Secretory immune system. Ann NY Acad Sci 409: 637Google Scholar
  69. 69.
    Thomson TA, Hilfenhaus J, Moser H, Morahan PS (1983) Comparison of effects of adjuvants on efficacy of virion envelope herpes simplex virus vaccine against labial infection of BALB/c mice. Infect Immun 41: 556PubMedGoogle Scholar
  70. 70.
    Wardlaw AC, Aprile MA (1967) Field trials of aluminium adjuvant vaccines and toxoids: A review. Intern. Symp. on Adjuvants of Immunity, Utrecht 1966; Symp. Series Immunobiol. Standard, vol. 6. Karger, Basel New York, p 257Google Scholar
  71. 71.
    Webster RG, Glezen WP, Hannoun C, Laver WG (1977) Potentiation of the immune response to influenza virus subunit vaccine. J Immunol 119: 2073PubMedGoogle Scholar
  72. 72.
    Woodard LF, Toone NM, McLaughlin CA (1980) Immunogenic properties of soluble antigens or whole cells ofBrucella abortus strain 45/20 associated with immunoadjuvants. I. Soluble antigens. Can J Comp Med 44: 453PubMedGoogle Scholar
  73. 73.
    Woodard LF, Toone NM, McLaughlin CA (1980) Immunogenic properties of soluble antigens or whole cells ofBrucella abortus strain 45/20 associated with immunoadjuvants. II. Whole cells. Can J Comp Med 44: 456PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • Louis Chedid
    • 1
  • Françoise Audibert
    • 1
  1. 1.C.N.R.S. UA-579, Immunothérapie ExpérimentaleInstitut PasteurParis Cedex 15France

Personalised recommendations